Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Aug 13, 2020
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how using a fitness tracker during radiotherapy can improve the quality of life for patients with certain types of cancer, such as lung, esophagus, brain, head and neck, pancreas, sarcoma, and cervical cancers. The researchers want to see if tracking physical activity helps patients feel better and cope with their treatment. They are currently recruiting participants aged 18 and older who are starting radiotherapy that will last at least four weeks and are in relatively good health.
To participate, individuals must be able to consent to the study and have a confirmed diagnosis of one of the specified cancers. However, those with severe heart conditions, limited mobility, or who are pregnant cannot join. Participants can expect to wear a fitness tracker and engage in a guided exercise program during their treatment, which may help them feel stronger and more energized as they go through their cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Capacity for consent
- • Minimum age 18
- • Presence of one of the following tumor diseases: Bronchial Carcinoma, Esophageal Carcinoma, Tumor of the Brain, Head and Neck Cancer, Pancreas Cancer, Sarcoma Cervix Uteri Cancer
- • ECOG 0-2
- • Indication for a radiotherapy or a radiochemotherapy with an intended treatment time of minimum 4 weeks (definitive/adjuvant/neoadjuvant)
- Exclusion Criteria:
- • Participation in any other interventional study
- • Radiotherapy of Breast cancer
- • Pregnancy
- • Contraindication against physical activity/sport and others
- • Severe cardiovascular pre-existing conditions (after myocardial infarction, apoplexy in the last 6 months, congestive heart failure NYHA \> I°)
- • preexisting diseases with are relevantly accompanied by a limited mobility in patients (e.g. paraparesis of the lower limbs)
- • ECOG Status 3-4
- • prior use of activity trackers
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
Tübingen, Baden Württemberg, Germany
Patients applied
Trial Officials
Cihan Gani, MD, PD
Principal Investigator
University Hospital Tübingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials